Skip to main content
. 2020 Jun 9;9(12):e015628. doi: 10.1161/JAHA.119.015628

Figure 2. Plasma concentrations of proteins discovered by SOMAscan measured by enzyme immunoassay in the whole study cohort over time.

Figure 2

Plasma levels of LBP (lipopolysaccharide‐binding protein), CCL23 (C‐C motif ligand 23) (cross‐reacts with Ck‐beta‐8‐1), HAMP (hepcidin antimicrobial peptide), IGFBP4 (insulin‐like growth factor‐binding 4), PRTN3 (proteinase 3), SerpinA3 (serpin family A member 3), VEGF (vascular endothelial growth factor A), and C5A (complement component 5a anaphylatoxin) during hospitalization (baseline to 3 days) and follow‐up (3 and 6 months) in patients with non–ST‐segment–elevation myocardial infarction receiving placebo (n=59) or tocilizumab (n=58) and analyzed according to whether the patient did (n=88) or did not (n=29) undergo percutaneous coronary intervention (PCI) (n=88). Circles and bars represent estimated marginal means and 95% CIs normalized for baseline values. The P value represents the effect of treatment.